Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR2219 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Hebei Taihe Chunyu Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR2219 CAR-T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target CD19 and CD22, two antigens frequently expressed on the surface of B-cell malignancies. By targeting both antigens, this therapy aims to reduce the risk of relapse caused by antigen escape, which is a common limitation of single-target CAR-T therapies. Developed by The First Medical Center of the PLA General Hospital in China, CAR2219 is currently being evaluated in Phase 1 clinical trials for patients with relapsed or refractory CD19+ and CD22+ B-cell lymphoma.
- Other names
- CD19/CD22 dual-targeted CAR-T cellsCD19-CD22 CAR-TCD-19-CD22 CAR-TCD 19-CD22 CAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CAR2219 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR2219 CAR-T cells.